Background/Aims: In type 1 diabetes (T1D), type 2 diabetes (T2D) and metabolic syndrome (MetS), the associated complex metabolomic changes in the involvement of carnitine metabolism in total carnitine ester level has already been documented; here we extended the investigations to the individual acylcarnitines. Methods: The fasting serum acylcarnitine concentrations were determined in 49 T1D, 38 T2D and 38 MetS patients and 40 controls by isotope dilution electrospray ionization tandem mass spectrometry. Results: The acylcarnitine profiles of the 3patient groups shared elements with the controls. Considerably higher levels of almost all short-chain acylcarnitines (p < 0.05) and lower levels of some long-chain acylcarnitines were detected in T2D and MetS patients. The amounts of C3 and C4 carnitine were higher and most of the medium-chain and long-chain acylcarnitine levels were lower (p < 0.05) in T1D and MetS patients than in the controls. In T1D and T2D, the levels of C3 and C4 acylcarnitines were markedly elevated and some long-chain acylcarnitines were lower than the controls (p < 0.05). Moreover, significantly lower concentrations of free- and total carnitine were observed in T1D patients (p < 0.05). Conclusions: Profound alterations were detected in acylcarnitine profiles in the 3 patient groups. Similarities in the patterns suggest different degrees of involvement of the same metabolic systems in a systems biology approach.

Keywords:
Carnitine ester profile, Diabetes mellitus, Metabolic syndrome, Mass spectrometry
1.
Bieber LL: Carnitine. Annu Rev Biochem 1988;57:261–283.
2.
Proulx F, Lacroix J, Qureshi IA, Nadeau D, Gauthier M, Lambert M: Acquired carnitine abnormalities in critically ill children. Eur J Pediatr 1997;156:864–869.
3.
Ferrannini E, Buzzigoli G, Bevilacqua S, Boni C, Del CD, Oleggini M, Brandi L, Maccari F: Interaction of carnitine with insulin-stimulated glucose metabolism in humans. Am J Physiol 1988;255:E946–E952.
4.
Capaldo B, Napoli R, Di BP, Albano G, Sacca L: Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1991;14:191–195.
5.
Genuth SM, Hoppel CL: Plasma and urine carnitine in diabetic ketosis. Diabetes 1979;28:1083–1087.
6.
De PE, Gatti R, Sicolo N, Padovan D, Vettor R, Federspil G: Plasma and urine free L- carnitine in human diabetes mellitus. Acta Diabetol Lat 1981;18:91–95.
7.
Okuda Y, Kawai K, Murayama Y, Yamashita K: Postprandial changes in plasma ketone body and carnitine levels in normal and non-insulin-dependent diabetic subjects. Endocrinol Jpn 1987;34:415–422.
8.
Pregant P, Kaiser E, Schernthaner G: No effect of insulin treatment or glycemic improvement on plasma carnitine levels in type 2 diabetic patients. Clin Investig 1993;71:610–612.
9.
Tamamogullari N, Silig Y, Icagasioglu S, Atalay A: Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications 1999;13:251–253.
10.
Poorabbas A, Fallah F, Bagdadchi J, Mahdavi R, Aliasgarzadeh A, Asadi Y, Koushavar H, Vahed JM: Determination of free L-carnitine levels in type II diabetic women with and without complications. Eur J Clin Nutr 2007;61:892–895.
11.
Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT: Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009;139:1073–1081.
12.
Cederblad G, Hermansson G, Ludvigsson J: Plasma and urine carnitine in children with diabetes mellitus. Clin Chim Acta 1982;125:207–217.
13.
Soltesz G, Melegh B, Sandor A: The relationship between carnitine and ketone body levels in diabetic children. Acta Paediatr Scand 1983;72:511–515.
14.
Winter SC, Simon M, Zorn EM, Szabo-Aczel S, Vance WH, O’Hara T, Higashi L: Relative carnitine insufficiency in children with type I diabetes mellitus. Am J Dis Child 1989;143:1337–1339.
15.
Mamoulakis D, Galanakis E, Dionyssopoulou E, Evangeliou A, Sbyrakis S: Carnitine deficiency in children and adolescents with type 1 diabetes. J Diabetes Complications 2004;18:271–274.
16.
Möder M, Kiessling A, Loster H, Bruggemann L: The pattern of urinary acylcarnitines determined by electrospray mass spectrometry: a new tool in the diagnosis of diabetes mellitus. Anal Bioanal Chem 2003;375:200–210.
17.
Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, DeLany JP: Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 2010;18:1695–1700.
18.
Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP: A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311–326.
19.
Costa CC, de Almeida IT, Jakobs C, Poll-The BT, Duran M: Dynamic changes of plasma acylcarnitine levels induced by fasting and sunflower oil challenge test in children. Pediatr Res 1999;46:440–444.
20.
Bene J, Komlosi K, Magyari L, Talian G, Horvath K, Gasztonyi B, Miheller P, Figler M, Mozsik G, Tulassay Z, Melegh B: Plasma carnitine ester profiles in Crohn’s disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. Br J Nutr 2007;98:345–350.
21.
Hoppel C: The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis 2003;41:S4–S12.
22.
Melegh B, Kerner J, Sandor A, Vinceller M, Kispal G: Effects of oral L-carnitine supplementation in low-birth-weight premature infants maintained on human milk. Biol Neonate 1987;51:185–193.
23.
Melegh B, Pap M, Morava E, Molnar D, Dani M, Kurucz J: Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. J Pediatr 1994;125:317–321.
24.
Vaz FM, Melegh B, Bene J, Cuebas D, Gage DA, Bootsma A, Vreken P, van Gennip AH, Bieber LL, Wanders RJ: Analysis of carnitine biosynthesis metabolites in urine by HPLC-electrospray tandem mass spectrometry. Clin Chem 2002;48:826–834.
25.
Melegh B, Kerner J, Acsadi G, Lakatos J, Sandor A: L-carnitine replacement therapy in chronic valproate treatment. Neuropediatrics 1990;21:40–43.
26.
Calvani M, Reda E, Arrigoni-Martelli E: Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol 2000;95:75–83.
27.
Millington DS, Kodo N, Norwood DL, Roe CR: Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 1990;13:321–324.
28.
Chace DH, Hillman SL, Van Hove JL, Naylor EW: Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997;43:2106–2113.
29.
Rashed MS: Clinical applications of tandem mass spectrometry: ten years of diagnosis and screening for inherited metabolic diseases. J Chromatogr B Biomed Sci Appl 2001;758:27–48.
30.
McGarry JD, Brown NF: The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997;244:1–14.
31.
Gaster M: Reduced TCA flux in diabetic myotubes: a governing influence on the diabetic phenotype? Biochem Biophys Res Commun 2009;387:651–655.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.